PF-514273

PF-514273

Identifiers
IUPAC name 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one
CAS Number	851728-60-4
PubChem (CID)	11316919
ChemSpider	9491886
Chemical and physical data
Formula	C21H17Cl2F2N3O2
Molar mass	452.281 g/mol
3D model (Jmol)	Interactive image
SMILES O=C1N(CC(F)(C)F)CCOc2c1nn(c2-c(cc4)ccc4Cl)-c3ccccc3Cl
InChI InChI=1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3 Key:FJMQJSUOOGOWBD-UHFFFAOYSA-N
(what is this?)

PF-514273 is a drug developed by Pfizer, which acts as an extremely selective antagonist for the CB₁ receptor, with approximately 10,000x selectivity over the closely related CB₂ receptor. This very high selectivity makes it useful for scientific research into these receptors, as many commonly used cannabinoid receptor antagonists also block the CB₂ receptor to some extent.^[1]

References

1. Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, Schneider SR, Paight ES, Griffith DA, Scott DO, O'Connor RE, Nduaka CI. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. Journal of Medicinal Chemistry. 2009 May 14;52(9):2652-5. PMID 19351113